Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"

被引：0
|
作者：
Jiang, Yanfang [1 ]
Zhang, Lei [2 ,3 ]
机构：
[1] First Hosp Jilin Univ, Genet Diag Ctr, Changchun, Peoples R China
[2] Med Res Ctr, Key Lab Digital Technol Med Diagnost Zhejiang Prov, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2024.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e43 / e43
页数：1
相关论文
共 50 条
  • [21] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [22] KRAS G12C inhibition with sotorasib in metastatic colorectal cancer
    Severi, Christophe
    Van Cutsem, Eric
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (08) : 2792 - 2795
  • [23] Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation
    Chen, Yuxi
    Hua, Chen
    Lin, Xiaoxi
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1259 - 1260
  • [24] Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
    Skoulidis, F.
    Schuler, M.
    Wolf, J.
    Barlesi, F.
    Price, T.
    Dy, G.
    Govindan, R.
    Borghaei, H.
    Falchook, G.
    Li, B.
    Ramalingam, S.
    Sacher, A.
    Spira, A.
    Takahashi, T.
    Anderson, A.
    Ang, A.
    Dai, T.
    Flesher, D.
    Cifuentes, P.
    Velcheti, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S929 - S930
  • [25] VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
    Hochmair, M. J.
    Vermaelen, K.
    Mountzios, G.
    Carcereny, E.
    Dooms, C.
    Lee, S. -h.
    Morocz, E. M.
    Kato, T.
    Ciuleanu, T-e.
    Dy, G.
    Parente, M. B. M. C. S.
    O'Byrne, K. J.
    Chu, Q. s -c.
    De Castro Jr, G.
    Girard, N.
    Snyder, W.
    Tran, Q.
    Kormany, W.
    Houk, B.
    Curioni-Fontecedro, A.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 142 - 144
  • [26] Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial
    Li, Bob T.
    Clarke, Jeffrey Melson
    Felip, Enriqueta
    Ruffinelli, Jose Carlos
    Garrido, Pilar
    Zugazagoitia, Jon
    Goldberg, Sarah B.
    Ramalingam, Suresh S.
    Victoria, Ivan
    Puri, Sonam
    Gandara, David R.
    Kormany, William
    Edmonds, Sophie
    Palmer, Kerry
    Gupta, Ravi G.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
    Kondo, S.
    Yan, D.
    Ganju, V.
    Richardson, G.
    Hou, X.
    Shan, J.
    Liu, X.
    Zhang, Y.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Wang, Y.
    Zhang, L.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S898 - S899
  • [28] KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
    Eser, Metin
    Hekimoglu, Gulam
    Yarar, Murat Hakki
    Canbek, Sezin
    Ozcelik, Melike
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation Reply
    Fraissenon, Antoine
    Guibaud, Laurent
    Canaud, Guillaume
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1260 - 1260
  • [30] Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC
    Karim, N.
    Waterhouse, D.
    Jones, S.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S719 - S720
12345